The future lies in &quot;biologics&quot;, which unlike small-molecule compounds, cannot be (that) easily copied&#x2F;manufactured. Initial and continuous capital costs prevent easy &quot;piracy&quot; and that is where the majority of large-pharam&#x2F;biotech R&amp;D is headed.